Filip Janku


Affiliation: The University of Texas
Country: USA


  1. Janku F, Stewart D, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. Nat Rev Clin Oncol. 2010;7:401-14 pubmed publisher
    ..Novel drugs aimed at these abnormalities are already in the clinic. This Review outlines the current state-of-the-art research for targeted therapy in NSCLC. ..
  2. Janku F, Garrido Laguna I, Petruzelka L, Stewart D, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011;6:1601-12 pubmed publisher
    ..This review describes molecular targets in non-small cell lung cancer that are in development or being clinically applied and their implications for developing novel anticancer therapies for this previously refractory malignancy. ..
  3. Janku F, Wheler J, Naing A, Falchook G, Hong D, Stepanek V, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013;73:276-84 pubmed publisher
    ..6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration. ..
  4. Liang W, Vergilio J, Salhia B, Huang H, Oki Y, Garrido Laguna I, et al. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist. 2018;: pubmed publisher
    ..Lastly, this work demonstrates that changes in the mutant allele frequency of XPO1 in serially collected plasma cell-free DNA samples correspond with treatment outcomes measured with conventional radiographic imaging. ..
  5. Jiang Y, Ludwig J, Janku F. Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev. 2015;41:391-400 pubmed publisher
  6. Mohammed A, Janku F, Qi M, Kurzrock R. Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. J Med Case Rep. 2015;9:45 pubmed publisher
    ..Our experience may also have broader implications in that it suggests that etiology of "mixed responses" should be confirmed by performing biopsies on the progressive tumor. ..
  7. Ganesan P, Janku F, Naing A, Hong D, Tsimberidou A, Falchook G, et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013;12:2857-63 pubmed publisher
    ..PIK3CA mutations are associated with simultaneous KRAS mutations, possibly accounting for therapeutic resistance. ..
  8. Janku F. Advances on the BRAF Front in Colorectal Cancer. Cancer Discov. 2018;8:389-391 pubmed publisher
    ..i>Cancer Discov; 8(4); 389-91. ©2018 AACRSee related article by Corcoran et al., p. 428See related article by Hazar-Rethinam et al., p. 417. ..
  9. Janku F, Huang H, Claes B, Falchook G, Fu S, Hong D, et al. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016;15:1397-404 pubmed publisher
    ..A higher percentage of mutant BRAF(V600) in cfDNA corresponded with shorter OS and in patients receiving BRAF/MEK inhibitors also with shorter TTF. Mol Cancer Ther; 15(6); 1397-404. ©2016 AACR. ..

More Information


  1. Janku F, Huang H, Angelo L, Kurzrock R. A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. Oncotarget. 2013;4:463-73 pubmed
    ..Collectively, these experiments suggest that IGF-1R, has kinase-independent biologic functions and provide a rationale for combining anti-IGF-1R antibodies or siRNA and IGF-1R small molecule inhibitors. ..
  2. Janku F, Hong D, Fu S, Piha Paul S, Naing A, Falchook G, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014;6:377-87 pubmed publisher
    ..This work provides further important clinical validation for continued and accelerated use of biomarker-driven trials incorporating rational drug combinations. ..
  3. Möhrmann L, Huang H, Hong D, Tsimberidou A, Fu S, Piha Paul S, et al. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018;24:181-188 pubmed publisher
    ..Low exoNA MAF is an independent prognostic factor for longer survival. Clin Cancer Res; 24(1); 181-8. ©2017 AACR. ..
  4. Janku F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treat Rev. 2017;59:93-101 pubmed publisher
  5. Wheler J, Atkins J, Janku F, Moulder S, Yelensky R, Stephens P, et al. Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer. 2015;15:442 pubmed publisher
    ..Further study of next generation sequencing-profiled tumors for convergence and resistance pathways is warranted. ..
  6. Sakamuri D, Glitza I, Betancourt Cuellar S, Subbiah V, Fu S, Tsimberidou A, et al. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018;17:671-676 pubmed publisher
    ..i>Mol Cancer Ther; 17(3); 671-6. ©2017 AACR. ..
  7. Fujii T, Barzi A, Sartore Bianchi A, Cassingena A, Siravegna G, Karp D, et al. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017;23:3657-3666 pubmed publisher
    ..Changes in mutated urine cfDNA were associated with time to treatment failure. Clin Cancer Res; 23(14); 3657-66. ©2017 AACR. ..
  8. Janku F, Wheler J, Naing A, Stepanek V, Falchook G, Fu S, et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012;3:1566-75 pubmed
    ..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors. ..
  9. Liu X, George G, Tsimberidou A, Naing A, Wheler J, Kopetz S, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015;15:713 pubmed publisher
    ..156). Our data lends support to the concept of clonal evolution, though the clinical impact appears less robust than previously reported. Further work to determine which patients benefit from retreatment post progression is needed. ..